glp-1 pros Garner's Pro Naturally optimize your appetite People think GLP-1 is just

Secondary, safety and negative control endpoints For individual components of the primary endpoint, semaglutide versus sitagliptin reduced myocardial infarction (HR 0.81, 95% CI 0.70 to 0.92) and stroke (HR 0.84, 95% CI 0.71 to 0.99) in the expanded populations at low, moderate and high cardiovascular risk

Acknowledgements This work is supported by the NSF-CREST Grant number HRD 1036494 and HRD 1547771, and NSF-IGERT

Individuals Already Using GLP-1 Medications Want to track progress independently Avoid repeated clinic visits 2

Both trials enrolled predominantly high-risk populations81% of LEADER and 83% of SUSTAIN-6 participants had established cardiovascular disease [3]